National Comprehensive Cancer Network
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Abstract
The NCCN Guidelines for Multiple Myeloma (MM) provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with MM. These NCCN Guidelines Insights highlight the important updates and changes specific to systemic therapy for patients with newly diagnosed as well as previously treated MM included in Version 1.2025 of the NCCN Guidelines for MM.
Source and rights
Published by Journal of the National Comprehensive Cancer Network : JNCCN, 2025. The guideline itself is at the source linked here.
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Organisation
- National Comprehensive Cancer Network
- Published
- 2025
- Applies to
- 🇺🇸 United States
- Scope
- National
- Journal
- Journal of the National Comprehensive Cancer Network : JNCCN
- PubMed
- 40340857
- Added to Prognia
- 22 July 2026
More in haematology
- Perceived relative clinical significance of the risks of venous thromboembolism and bleeding from pharmacologic thromboprophylaxis in children: an international survey of pediatric providers: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and HemostasisInternational Society on Thrombosis and Haemostasis · 2026
- Evidence-based AGIHO guideline update on prophylaxis of infectious complications with granulocyte-stimulating factors (G-CSF) for the treatment of adult patients with cancerInfectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) · 2026
